360
Participants
Start Date
April 24, 2023
Primary Completion Date
May 1, 2027
Study Completion Date
May 1, 2028
Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)
"Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation"
Repeat local treatment
"Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection)."
RECRUITING
Amsterdam UMC, Amsterdam
Amsterdam UMC, location VUmc
OTHER